Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis.
Brendan M. Everett,Aruna D. Pradhan,Aruna D. Pradhan,Daniel H. Solomon,Nina P. Paynter,Jean G. MacFadyen,Elaine Zaharris,Milan Gupta,Michael Clearfield,Peter Libby,Ahmed A. K. Hasan,Robert J. Glynn,Paul M. Ridker +12 more
Reads0
Chats0
TLDR
If low-dose methotrexate reduces cardiovascular events, CIRT would provide a novel therapeutic approach for the secondary prevention of heart attack, stroke, and cardiovascular death.About:
This article is published in American Heart Journal.The article was published on 2013-08-01 and is currently open access. It has received 347 citations till now. The article focuses on the topics: Myocardial infarction & Rheumatoid arthritis.read more
Citations
More filters
Journal ArticleDOI
Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond
Aaron W. Aday,Paul M. Ridker +1 more
TL;DR: The CANTOS trial results mark the first phase 3 trial results validating inflammation as a viable target for preventing cardiovascular disease and highlight previous trial data showing its modulation with statins and other agents.
Journal ArticleDOI
Interleukin-6 in atherosclerosis: atherogenic or atheroprotective?
TL;DR: Interleukin-6, a unique pleiotropic cytokine exhibiting both pro- and anti-inflammatory properties depending on the target cell type, has been evaluated as an atheroprotective agent, but studies are inconclusive.
Journal ArticleDOI
Targeting inflammatory pathways for the treatment of cardiovascular disease
TL;DR: The core question raised in the present analysis does not relate to which inflammatory biomarker is best suited for clinical practice, but rather to whether the incremental utility of C-reactive protein for predicting vascular risk was found to be fully comparable to that of total and high-density lipoprotein cholesterol.
Journal ArticleDOI
Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease
TL;DR: Modulation of the inflammatory response is a new and promising approach in the therapy of cardiovascular disease and classical anti-inflammatory therapeutic compounds, but also established drugs with pleiotropic immunomodulatory abilities, demonstrated protective effects in various models of cardiovascular Disease.
Journal ArticleDOI
The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis.
Angela Pirillo,Fabrizia Bonacina,Giuseppe Danilo Norata,Giuseppe Danilo Norata,Alberico L. Catapano +4 more
TL;DR: The novel acquisitions in pathophysiology of atherosclerosis reinforce the tight link between lipids, inflammation, and immune response, and support the benefit of targeting LDL-C as well as inflammation to decrease the CVD burden.
References
More filters
Journal ArticleDOI
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein,Michael Miller,Robert P. Byington,David C. Goff,J. Thomas Bigger,John B. Buse,William C. Cushman,Saul Genuth,Faramarz Ismail-Beigi,Faramarz Ismail-Beigi,Richard H. Grimm,Jeffrey L. Probstfield,Denise G. Simons-Morton,William T. Friedewald +13 more
TL;DR: In this paper, the authors investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors.
Journal ArticleDOI
Definition of Metabolic Syndrome Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition
TL;DR: Although ATP III identified CVD as the primary clinical outcome of the metabolic syndrome, most people with this syndrome have insulin resistance, which confers increased risk for type 2 diabetes, when diabetes becomes clinically apparent, CVD risk rises sharply.
Journal ArticleDOI
C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women
TL;DR: The addition of the measurement of C-reactive protein to screening based on lipid levels may provide an improved method of identifying persons at risk for cardiovascular events.
Journal ArticleDOI
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M. Ridker,Eleanor Danielson,Jacques Genest,Antonio M. Gotto,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +11 more
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Journal ArticleDOI
Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men
TL;DR: The reduction associated with the use of aspirin in the risk of a first myocardial infarction appears to be directly related to the level of C-reactive protein, raising the possibility that antiinflammatory agents may have clinical benefits in preventing cardiovascular disease.
Related Papers (5)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker,Brendan M. Everett,Tom Thuren,Jean G. MacFadyen,William Chang,Christie M. Ballantyne,Francisco H. Fonseca,Jose C. Nicolau,Wolfgang Koenig,Stefan D. Anker,John J.P. Kastelein,Jan H. Cornel,Prem Pais,Daniel Pella,Jacques Genest,Renata Cifkova,Alberto J. Lorenzatti,Tamás Forster,Zhanna Kobalava,Luminita Vida-Simiti,Marcus Flather,Hiroaki Shimokawa,Hisao Ogawa,Mikael Dellborg,Paulo Roberto Ferreira Rossi,Roland P.T. Troquay,Peter Libby,Robert J. Glynn +27 more
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Peter Duewell,Hajime Kono,Katey J. Rayner,Katey J. Rayner,Cherilyn M. Sirois,Gregory I. Vladimer,Franz Bauernfeind,George S. Abela,Luigi Franchi,Guillermo Gabriel Nuñez,Max Schnurr,Terje Espevik,Egil Lien,Katherine A. Fitzgerald,Kenneth L. Rock,Kathryn J. Moore,Kathryn J. Moore,Samuel D. Wright,Veit Hornung,Eicke Latz,Eicke Latz +20 more